GENinCode H1 revenues grow, losses unchanged YOY.

Predictive genetics firm GENinCode said on Tuesday that interim losses were unchanged year-on-year but noted that it had seen "continued strengthening of business" in the six months ended 30 June.

GENinCode
26 August 2025 10:35:24

Source: Sharecast

GENinCode said first-half revenues were up 15% at £1.6m, driven by growth across the UK, EU and US business, while gross profit margins remained firm at 53%. Underlying losses were also unchanged in H1 at £2.4m.

Cash at the end of June was £2.4m, down from £2.9m a year earlier, but GENinCode said trading remained "broadly in line with the board's overall expectations for the full year", with the firm pointing to "a busy second half period" ahead.

On the operational front, GENinCode said US Food and Drug Administration De Novo discussions continued to progress, with work ongoing to close out the short list of remaining deficiencies, while collaboration discussions on potential US and EU test distribution were also said to be advancing with "a major distributor".

As of 1030 BST, GENinCode shares were up 6.49% at 1.49p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.